Walla Walla East, WA, United States
Walla Walla East, WA, United States

Time filter

Source Type

Patent
Infectious Disease Research Institute | Date: 2017-02-01

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided:_(1), L_(2), L_(3), L_(4), L_(5), L_(6), L_(7), L_(8), L_(9), L_(10), Y_(1), Y_(2), Y_(3), Y_(4), R_(1), R_(2), R_(3) , R_(4), R_(5), R_(6), are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.


Patent
Infectious Disease Research Institute | Date: 2016-10-04

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L_(1), L_(2), L_(3), L_(4), L_(5), L_(6), L_(7), L_(8), L_(9), L_(10), Y_(1), Y_(2), Y_(3), Y_(4), R_(1), R_(2), R_(3), R_(4), R_(5), R_(6), are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.


Reed S.G.,Infectious Disease Research Institute | Orr M.T.,Infectious Disease Research Institute | Fox C.B.,Infectious Disease Research Institute
Nature Medicine | Year: 2013

Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs. However, many adjuvants fail during product development owing to factors such as manufacturability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns. This Review outlines the potential benefits of adjuvants in current and future vaccines and describes the importance of formulation and mechanisms of action of adjuvants. Moreover, we emphasize safety considerations and other crucial aspects in the clinical development of effective adjuvants that will help facilitate effective next-generation vaccines against devastating infectious diseases. © 2013 Nature America, Inc.


Patent
Infectious Disease Research Institute | Date: 2014-05-23

The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.


Patent
Infectious Disease Research Institute | Date: 2014-12-29

The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.


Patent
Infectious Disease Research Institute | Date: 2014-03-21

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L_(1), L_(2), L_(3), L_(4), L_(5), L_(6), L_(7), L_(8), L_(9), L_(10), Y_(1), Y_(2), Y_(3), Y_(4), R_(1), R_(2), R_(3), R_(4), R_(5), R_(6), are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.


Patent
Infectious Disease Research Institute | Date: 2014-03-28

Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising one or more Leishmania antigens as well as polynucleotides encoding such polypeptides.


Patent
Infectious Disease Research Institute | Date: 2014-09-12

Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more Leishmania antigens, or a variant thereof. Additionally, methods of screening a screening library for tandem repeat proteins that have immunogenic properties are disclosed. Vaccines and pharmaceutical compositions comprising polynucleotides, polypeptides, fusion proteins and variants thereof that may be used for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmaniasis infection are described.


Patent
Infectious Disease Research Institute | Date: 2015-09-09

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.


Patent
Infectious Disease Research Institute | Date: 2014-03-28

Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising Leishmania antigens as well as polynucleotides encoding such polypeptides.

Loading Infectious Disease Research Institute collaborators
Loading Infectious Disease Research Institute collaborators